Article
Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders.
The Journal of allergy and clinical immunology - 1 Jan 2018
Slack James, Albert Michael H, Balashov Dmitry, Belohradsky Bernd H, Bertaina Alice, Bleesing Jack, Booth Claire, Buechner Jochen, Buckley Rebecca H, Ouachée-Chardin Marie, Deripapa Elena, Drabko Katarzyna, Eapen Mary, Feuchtinger Tobias, Finocchi Andrea, Gaspar H Bobby, Ghosh Sujal, Gillio Alfred, Gonzalez-Granado Luis I, Grunebaum Eyal, Güngör Tayfun, Heilmann Carsten, Helminen Merja, Higuchi Kohei, Imai Kohsuke, Kalwak Krzysztof, Kanazawa Nubuo, Karasu Gülsün, Kucuk Zeynep Y, Laberko Alexandra, Lange Andrzej, Mahlaoui Nizar, Meisel Roland, Moshous D, Muramatsu Hideki, Parikh Suhag, Pasic Srdjan, Schmid Irene, Schuetz Catharina, Schulz Ansgar, Schultz Kirk R, Shaw Peter J, Slatter Mary A, Sykora Karl-Walter, Tamura Shinobu, Taskinen Mervi, Wawer Angela, Wolska-Kuśnierz Beata, Cowan Morton J, Fischer Alain, Gennery Andrew R
Abstract excerpt
BACKGROUND: Rare DNA breakage repair disorders predispose to infection and lymphoreticular malignancies. Hematopoietic cell transplantation (HCT) is curative, but coadministered chemotherapy or radiotherapy is damaging because of systemic radiosensitivity. We collected HCT outcome data for Nijmegen breakage syndrome, DNA ligase IV deficiency, Cernunnos-XRCC4-like factor (Cernunnos-XLF) deficiency, and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.